ZUP1 and myeloid neoplasm: A few examples of pharmacological DUB inhibitors inducing protein degradation for therapeutic benefit have been reported in hematologic malignancy models, including myeloid neoplasms [265,352,353,354] and multiple myeloma [353,355,356].